Melanoma – Randomized Phase II Study of AB (nab-paclitaxel Abraxane, Bevacizumab) versus Ipilimumab for Therapy of Unresectable Stage IV Metastatic Malignant Melanoma
Melanoma – Randomized Phase II Study of AB (nab-paclitaxel Abraxane, Bevacizumab) versus Ipilimumab for Therapy of Unresectable Stage IV Metastatic Malignant Melanoma